Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, et al. - Ustekinumab (UST; a biologic agent) therapy appears to be a safe choice for patients with resolved HBV infection. This inference was drawn considering both the available literature and results from observations.

• Biological therapies employed to treat psoriasis pose a risk of reactivation of HBV infection.

• This retrospective analysis included 106 patients with moderate to severe psoriasis treated with biological therapy; of these, 5 patients reported having past HBV.

• All 5 patients received UST.

• In this cohort, resolved HBV infection was detected in 5 patients: HBsAg (-), HBcAb (+) and HBV DNA (-); 4/5 were HBsAb (+) and 1/5 HBsAb.

• Rise in LFTs values was not seen in any of the cases, and no signs of hepatitis or HBV reactivation were found at any point during the study.

• At the end of the follow up span, all cases were HBsAg and HBV DNA negative.

• Average treatment time and average follow up time was 82.4 (28, 96) weeks and 75.2 (31, 176) weeks, respectively.